Prothena Corp Public (PRTA) EBT Margin (2012 - 2026)
Prothena Corp Public's (PRTA) quarterly EBT Margin came in at 64.06% in Q1 2026, up 223425.0% year-on-year from N/an in Q1 2025, and up 100.06% quarter-over-quarter from 102757.14% in Q4 2025.
Prothena Corp Public (PRTA) EBT Margin (2012 - 2026) Analysis & Trends
Prothena Corp Public's EBT Margin history runs 15 years deep, the most recent figure standing at 64.06% for Q1 2026.
- On a quarterly basis, EBT Margin rose 223425.0% year-over-year to 64.06% in Q1 2026; TTM through Mar 2026 was 184.21%, a 10022.0% decrease from a year earlier, with the FY2025 full-year figure at 2073.82%, down 197843.0% from the prior year.
- EBT Margin climbed to 64.06% in Q1 2026 per PRTA's latest filing, from 102757.14% in the prior quarter.
- Across five years, EBT Margin topped out at 64.06% in Q1 2026 and bottomed at 148880.0% in Q1 2024.
- The 5-year median for EBT Margin is 2294.88% (2023), against an average of 17754.92%.
- Across the five-year window, EBT Margin tumbled 14658512 bps in 2024 and surged 14670981 bps in 2025, its largest moves.
- Year by year, EBT Margin stood at 6.7% in 2022, then tumbled by 333628 bps to 22347.47% in 2023, then soared by 87 bps to 2802.68% in 2024, then slumped by 3566 bps to 102757.14% in 2025, then jumped by 100 bps to 64.06% in 2026.
- Per Business Quant, the three latest PRTA EBT Margin figures stand at 64.06% (Q1 2026), 102757.14% (Q4 2025), and 1528.45% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Prothena Corp Public | 458.13 Mn | 128.67 Mn | - | 64.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 64.06% |
| Dec 31, 2025 | -102,757.14% |
| Sep 30, 2025 | -1,528.45% |
| Jun 30, 2025 | -1,831.79% |
| Mar 31, 2025 | -2,170.19% |
| Dec 31, 2024 | -2,802.68% |
| Sep 30, 2024 | -6,168.66% |
| Jun 30, 2024 | 49.12% |
| Mar 31, 2024 | -148,880.00% |
| Dec 31, 2023 | -22,347.47% |
| Sep 30, 2023 | 22.17% |
| Jun 30, 2023 | -1,465.56% |
| Mar 31, 2023 | -2,294.88% |
| Dec 31, 2022 | 6.70% |
| Sep 30, 2022 | -3,191.63% |
| Jun 30, 2022 | -3,244.82% |
| Mar 31, 2022 | -3,292.37% |
| Dec 31, 2021 | -2,823.89% |
| Sep 30, 2021 | 78.46% |
| Jun 30, 2021 | 46.44% |